[
 {
  "document": {
   "authors": "Thrishna",
   "contact_info": "thrishna@causalitybiomodels.com",
   "copyright": "Copyright \u00a9 2020 Fraunhofer Institute SCAI, All rights reserved",
   "description": "COVID Knowledge Curation project",
   "licences": "Private Ownership to Fraunhofer Institute SCAI",
   "name": "32220278.bel",
   "version": "2.0.0"
  }
 },
 {
  "definitions": [
   {
    "namespace": {
     "keyword": "HGNC",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hgnc/hgnc-20190708.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "GFAM",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hgnc-gene-families/hgnc-genefamily-names-20181221.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "CHEBI",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/chebi/chebi-20190708.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "PFAM",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/pfam/pfam-names-20181024.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "DO",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20200407.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "GO",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/go/go-20180109.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "TAX",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/ncbi-taxonomy/ncbi-taxonomy-20200322.belns",
     "value_list": []
    }
   },
   {
    "annotation": {
     "keyword": "BioAssay",
     "type": "PATTERN",
     "value": ".*",
     "value_list": []
    }
   },
   {
    "annotation": {
     "keyword": "Custom_Disease",
     "type": "LIST",
     "value": null,
     "value_list": [
      "COVID-19"
     ]
    }
   },
   {
    "annotation": {
     "keyword": "Type_Of_Infection",
     "type": "LIST",
     "value": null,
     "value_list": [
      "secondary infection"
     ]
    }
   },
   {
    "annotation": {
     "keyword": "PublicationType",
     "type": "LIST",
     "value": null,
     "value_list": [
      "Letter"
     ]
    }
   },
   {
    "annotation": {
     "keyword": "PublicationStatus",
     "type": "LIST",
     "value": null,
     "value_list": [
      "Published"
     ]
    }
   },
   {
    "annotation": {
     "keyword": "Section",
     "type": "LIST",
     "value": null,
     "value_list": [
      "Full Text"
     ]
    }
   }
  ]
 },
 {
  "statements_and_sets": [
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32220278",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "PublicationType": [
        "Letter"
       ]
      }
     },
     {
      "set": {
       "PublicationStatus": [
        "Published"
       ]
      }
     },
     {
      "set": {
       "Section": [
        "Full Text"
       ]
      }
     },
     {
      "evidence": "Mehta and colleagues postulate that hyperinflammation in coronavirus \\\ndisease 2019 (COVID-19) could be a driver of severity that is amenable \\\nto therapeutic targeting since retro spective data have shown that \\\nsystemic inflammation is associated with adverse outcome"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "COVID-19"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "inflammatory response"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "evidence": "However, correlation does not equal causation, and it is equally \\\nplausible that increased virus burden (secondary to failure of the \\\nimmune response to control infection) drives inflammation and \\\nconsequent severity (as shown for other viruse) rather than augmented \\\ninflammation being an inappropriate host response that requires \\\ncorrection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "TAX",
         "name": "Severe acute respiratory syndrome coronavirus 2"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "inflammatory response"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "evidence": "The authors hypothesise that approaches such as corticosteroids or \\\nJanus kinase (JAK) inhibitors could be considered if hyperinflammation \\\nis present."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "corticosteroid"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "inflammatory response"
        }
       ]
      ]
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "activity"
        }
       },
       [
        [
         {
          "function": {
           "type": "abundance",
           "name": "protein"
          }
         },
         [
          {
           "namespace": "GFAM",
           "name": "Jak family tyrosine kinases"
          }
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "inflammatory response"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "evidence": "Accordingly, findings from multiple studies in humans and animals \\\nindicate that corticosteroid immunosuppression (both inhaled and \\\nsystemic) impairs induction of anti-viral type-I interferon responses \\\nto a range of respiratory viruses,3,4 effects that are likely to also \\\noccur in the context of COVID-19."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "corticosteroid"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "immune response"
        }
       ]
      ]
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "immune response"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "type I interferon signaling pathway"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "evidence": "JAK-STAT signalling is a major component of the type-I interferon \\\npathway."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "type I interferon signaling pathway"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "JAK-STAT cascade"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "evidence": "Tofacitinib has been shown to inhibit interferon\u03b1 production in vitro. \\\nSuppression of interferon or other mediators (eg, interleukin 6) could \\\nalso promote secondary bacterial infection and further complicate the \\\ndisease course."
     },
     {
      "set": {
       "BioAssay": [
        "in vitro"
       ]
      }
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "tofacitinib"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "interferon-alpha secretion"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "unset": [
       "BioAssay"
      ]
     },
     {
      "set": {
       "Type_Of_Infection": [
        "secondary infection"
       ]
      }
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "activity"
        }
       },
       [
        [
         {
          "function": {
           "type": "abundance",
           "name": "protein"
          }
         },
         [
          {
           "namespace": "PFAM",
           "name": "Interferon"
          }
         ]
        ]
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "bacterial infectious disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "activity"
        }
       },
       [
        [
         {
          "function": {
           "type": "abundance",
           "name": "protein"
          }
         },
         [
          {
           "namespace": "HGNC",
           "name": "IL6"
          }
         ]
        ]
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "bacterial infectious disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "unset": [
       "Type_Of_Infection"
      ]
     },
     {
      "unset": [
       "PublicationType"
      ]
     },
     {
      "unset": [
       "PublicationStatus"
      ]
     },
     {
      "unset": [
       "Section"
      ]
     }
    ]
   }
  ]
 }
]